A figure showing HR 0.70 and zoomed in look of a separation of the curves 6.7% vs 9.4%

#Giredestrant oral SERD ➡️ incredible 30% benefit for those with early stage ER+ #breastcancer.

It's not on the market yet but other similar #bcsm 💊 cost >$20k/mo vs generic AI $7.50 (on CPD w/o insurance). Let's see some affordable pricing please.🙏
#SABCS25 #financialToxicity

Genentech: Press Releases | Monday, Nov 17, 2025 Discover the latest news about our company, our products, our policies, and our people.

🔴 #Breaking : #Giredestrant 🧬 de #Genentech devient la première #SERD orale à montrer une survie invasive sans maladie supérieure dans le #CancerDuSein précoce.

👉 Résultats positifs de phase III de l’étude #LidERA

#BreastCancer 🦀 #ESMO25
www.gene.com/media/press-...

From #ESMO2025 - Dr. Erica Mayer highlights the benefit of treatment with #giredestrant plus #everolimus in patients with ER-positive, HER2-negative advanced #BreastCancer who have previously received a CDK4/6 inhibitor.

Watch now 👉 buff.ly/D0apqEh

#MedNews #OncSky

Promising Results from the EMPRESS Study Highlight Giredestrant's Efficacy in Treating Early-Stage ER+/HER2- Breast Cancer The EMPRESS study showcases giredestrant's potential in treating early-stage ER+/HER2- breast cancer without ovarian suppression, promising better outcomes for patients.

Promising Results from the EMPRESS Study Highlight Giredestrant's Efficacy in Treating Early-Stage ER+/HER2- Breast Cancer #None #Breast_Cancer #EMPRESS_study #giredestrant

Genentech: Press Releases | Sunday, Sep 21, 2025 Discover the latest news about our company, our products, our policies, and our people.

Des résultats positifs de phase III montrent que le #Giredestrant 🧬 de #Genentech 🇺🇸, membre du groupe #Roche 🇨🇭 (SIX : RO, ROG ; OTCQX : RHHBY), a considérablement amélioré la survie sans progression dans le #CancerDuSein avancé RE positif
www.gene.com/media/press-...